Improving immune therapy for Type 1 diabetes
Enhancing antigen-based therapy for T1D by T cell coreceptor tuning
This study is testing a new treatment for Type 1 diabetes that helps your body protect the insulin-making cells by boosting a special part of your immune system, and it’s designed for people with T1D who want better ways to manage their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10739303 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy for Type 1 diabetes (T1D) by enhancing the body's immune response to protect insulin-producing cells. The approach involves administering specific proteins from these cells to stimulate the production of regulatory T cells, which can help control the autoimmune response that damages these cells. By tuning the function of a key immune receptor, the researchers aim to increase the effectiveness of this therapy while minimizing harmful immune reactions. This innovative method could lead to long-term management or prevention of T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of developing Type 1 diabetes or those in the early stages of the disease.
Not a fit: Patients with established Type 1 diabetes who are not in the early stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new way to prevent or treat Type 1 diabetes, reducing the need for daily insulin injections.
How similar studies have performed: Other research has shown promise in using immunotherapies to target autoimmune responses, suggesting that this approach may also be effective.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Tisch, Roland M — Univ of North Carolina Chapel Hill
- Study coordinator: Tisch, Roland M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.